title: Glycoprotein D adjuvant herpes simplex virus vaccine.
abstract: Herpes simplex virus (HSV) Type-1 and -2 are common infections that can cause primary and recurrent herpes labialis and genitalis, as well as gingivostomatitis, keratoconjunctivitis, encephalitis, disseminated infections in immunocompromised persons and neonatal infections. Despite several decades of HSV vaccine development, no effective vaccine has been developed until recently. The following review of the genital HSV-2 glycoprotein D (gD2t, t is for truncated) subunit vaccine formulated with a new adjuvant (AS04) containing alum and 3-O deacylated monophosphoryl lipid A (MPL) provides a background in which to evaluate the vaccine as well as a brief review of other approaches to herpes vaccines. The gD2t-AS04 vaccine has been demonstrated to be safe in several large clinical trials. In two trials, the vaccine reduced genital herpes disease by 73 and 74%, but only in females with no previous HSV infection. A large ongoing trial in HSV seronegative females will provide additional data on protection from HSV disease and infection.
authors.affiliation: Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati, Cincinnati, OH 45229, USA. david.bernstein@cchmc.org
authors.forename: David
authors.initials: D
authors.lastname: Bernstein
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000534:Alum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D002626:Chemistry, Pharmaceutical; D002648:Child; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000517:prevention & control; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D014611:Vaccination / Q000639:trends*; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D022301:Herpes Simplex Virus Vaccines; D008050:Lipid A; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2; C041524:aluminum sulfate; C048436:monophosphoryl lipid A